Aisling Capital Management LP has disclosed 16 total holdings in their latest 13F filing with the SEC for the portfolio
date of 2022-12-31. The current portfolio value is calculated to be $151.00 Mil. The turnover rate is 0%.
In Aisling Capital Management LP's current portfolio as of 2022-12-31, the top 5 holdings are
BridgeBio Pharma Inc (BBIO), Verona Pharma PLC (VRNA), Syndax Pharmaceuticals Inc (SNDX), Monte Rosa Therapeutics Inc (GLUE), Aclaris Therapeutics Inc (ACRS),
not including call and put options.
Aisling Capital Management LP did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the current and past 13F holdings for Aisling Capital Management LP, as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at
52-week lows, etc.
Please visit the "Stock Picks" tab to see the latest guru trades and stock picks for Aisling Capital Management LP, which include data from
13F quarterly reports, 13D/G beneficial ownership reports and form 4 insider ownership change reports.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Aisling Capital Management LP.